Ala Eddin Sagar/LinkedIn
Mar 22, 2026, 16:21
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center – Madinah, shared a post on LinkedIn:
Apixaban or rivaroxaban for acute VTE?
This study is one of three papers discussed in this week’s episode of This Week in Pulmonary and Critical Care Medicine.
We review:
- A randomized trial comparing apixaban vs rivaroxaban for VTE
- An ICU study on oscillatory airway therapy in ventilated patients
- A teaching discussion on how mitral valve disease affects the lungs
Curious how others are interpreting the DOAC trial.
Do you favor apixaban or rivaroxaban for acute VTE?
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST
-
Jun 26, 2026, 07:10Saleh Shamse Basha: Why APTT Alone Can Be Misleading During UFH Monitoring
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk
-
Jun 26, 2026, 05:55Shinya Goto: How Newton’s Laws Shape Platelet Function
-
Jun 26, 2026, 05:50Andrew Emad: Five Years of Partnership, Innovation, and Impact at Africa Health ExCon 2026
-
Jun 26, 2026, 05:48Regan Bucciol: The Emerging Role of Erythrocytes in Thrombosis
-
Jun 26, 2026, 05:26Maxime Dely: Strengthening Skills in Plasma and Red Cell Exchange
-
Jun 26, 2026, 05:26Andreas Calatzis: Hidden Differences in Anti-Xa Testing